Morihito Okada

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

Hisashi Saji, Morihito Okada, Masahiro Tsuboi et al. · The Lancet · 2022 · 1.5K citations

Surgical Oncology, Medicine, Cancer Management +10

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study

Morihito Okada, Teruaki Koike, Masahiko Higashiyama et al. · Journal of Thoracic and Cardiovascular Surgery · 2006 · 718 citations · Full text

Surgical Oncology, Medicine, Cancer Management +8

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8

Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

Kenji Suzuki, Hisashi Saji, Keiju Aokage et al. · Journal of Thoracic and Cardiovascular Surgery · 2019 · 488 citations · Full text

Interventional Pulmonology, Pulmonary Care, Outcomes Research +8

Appropriate Sublobar Resection Choice for Ground Glass Opacity-Dominant Clinical Stage IA Lung Adenocarcinoma

Yasuhiro Tsutani, Yoshihiro Miyata, Haruhiko Nakayama et al. · CHEST Journal · 2013 · 310 citations

Surgical Oncology, Interventional Pulmonology, Medical Imaging +6